Reply

We thank Dr Kocatürk and associates for their thoughtful correspondence regarding our manuscript. First, inflammation plays a critical role in the development of corneal neovascularization; therefore, inflammation received careful consideration in the development of our clinical study. Because we utilized a clinic-based population, it was not possible to standardize baseline levels of ocular surface inflammation. Most of the study patients were on one or more medications that could directly or indirectly affect ocular surface inflammation. In order to minimize the potential confounding effects of inflammation, only patients with clinically stable corneal neovascularization were considered for inclusion. Additionally, we excluded patients who had recently undergone a change in dose or frequency of topical anti-inflammatory therapy. Although punctal plugs may lead to a slight increase in the local bioavailability of these maintenance medications, it is unlikely that this caused a measurable response in 3 weeks. Eighteen out of 20 total patients (90%) completed 24 weeks of follow-up. Fifteen out of the 18 remaining patients (83%) exhibited decreases in neovascular area and vessel caliber. Although there were several nonresponders, topical bevacizumab proved to be effective in a majority of cases.